- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
The evolution of preclinical models for myelodysplastic neoplasms ; volume:38 ; number:4 ; day:23 ; month:2 ; year:2024 ; pages:683-691 ; date:4.2024
Leukemia ; 38, Heft 4 (23.2.2024), 683-691, 4.2024
- Urheber
-
Mina, Alain
Pavletic, Steven
Aplan, Peter D.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-024-02181-2
- URN
-
urn:nbn:de:101:1-2406211210132.273056369928
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mina, Alain
- Pavletic, Steven
- Aplan, Peter D.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
Nontraumatic acute subdural hematoma associated with the myelodysplastic/myeloproliferative neoplasms
Molecular characterization of patients with chronic myeloid leukemia and myeloproliferative/myelodysplastic neoplasms
Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
Functional characterisation of the mesenchymal cell-derived extracellular matrix in myelodysplastic neoplasms
Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis
Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
Nontraumatic acute subdural hematoma associated with the myelodysplastic/myeloproliferative neoplasms
Molecular characterization of patients with chronic myeloid leukemia and myeloproliferative/myelodysplastic neoplasms
Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
Functional characterisation of the mesenchymal cell-derived extracellular matrix in myelodysplastic neoplasms
Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis
Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
Nontraumatic acute subdural hematoma associated with the myelodysplastic/myeloproliferative neoplasms
Molecular characterization of patients with chronic myeloid leukemia and myeloproliferative/myelodysplastic neoplasms
Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
Functional characterisation of the mesenchymal cell-derived extracellular matrix in myelodysplastic neoplasms
Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis
Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice